Skip to search formSkip to main contentSkip to account menu

infliximab Injection [Inflectra]

National Institutes of Health

Related topics

Related topics

3 relations
InflectraInjection

Narrower (1)

infliximab-dyyb 100 MG Injection [Inflectra]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Biosimilar infliximab administration for the management of acute graft-versus-host disease
Introduction Acute graft-versus-host disease (aGVHD) is a significant immune-mediated complication of allogeneic hematopoietic… 
2019
2019
P725 A prospective study of planned switch from Infliximab originator remicade to biosimilar inflectra: a multi-centre Irish experience
2018
2018
Kosten-Nutzwert-Analyse der Biosimilar-Therapie bei ankylosierender Spondylitis in Deutschland
Zusammenfassung Hintergrund Tumornekrosefaktor-α-Inhibitoren für die Behandlung entzündlich-rheumatischer Erkrankungen gehören zu… 
Review
2017
Review
2017
P334 Medication adherence in diverse inner city pediatric patients with inflammatory bowel disease and comparison to physician perception of adherence.
s of the 12th Congress of ECCO – European Crohn’s and Colitis Organisation S247 from the UK Inflammatory Bowel Disease (IBD… 
2017
2017
Late Breaking Abstract - Promising results of the infliximab biosimilar Inflectra® in severe sarcoidosis patients
Background: Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-α) is effective third-line therapy for… 
2017
2017
P631 Results and predictors of outcome of endoscopic balloon dilation of colonic strictures in inflammatory bowel diseases.
2017
2017
P.05.16: CT-P13 (Inflectra® and Remsima®) Short Infusion (1-Hour Infusion) in Patients with Inflammatory Bowel Diseases: Data from a Tertiary Referral Center
2016
2016
CT-P13 (Inflectra™, Remsima™) monitoring in patients with inflammatory bowel disease.
2016
2016
Challenges Ahead for Newly Approved Biosimilar Inflectra
The U.S. approval of the first biosimilar in rheumatology, Inflectra, has been welcome news. Still, concerns about safety… 
2016
2016
Tolérance et efficacité d’un biosimilaire de l’infliximab dans les indications hors AMM : suivi prospectif d’une cohorte de patients en médecine interne (registre BIOSIM)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)